Literature DB >> 25292088

Metabolic syndrome prevalence in renal cell cancer patients.

Suleyman Bulut1, Binhan Kagan Aktas, Akif Ersoy Erkmen, Cuneyt Ozden, Cevdet Serkan Gokkaya, Mehmet Murat Baykam, Ali Memis.   

Abstract

PURPOSE: Renal cell carcinoma (RCC) is increasingly being recognized as a metabolic disease in recent studies. The aim of the present study was to identify the prevalence of metabolic syndrome (MetS) and its association with RCC among urologic patients.
MATERIALS AND METHODS: The study included a total of 355 participants (117 adult RCC patients and 238 age matched controls) divided into groups, with and without MetS diagnosed using the criteria of the American Heart Association/The National Heart Lung and Blood Institute. Groups were compared statistically and logistic regression analysis was performed to investigate the impact of MetS criteria on RCC risk.
RESULTS: Of the 117 RCC patients, 52 (44.4%) and of the 238 controls, 37 (15.5%) had MetS. A significant association (p<0.001) was found between the presence of MetS and RCC (OR: 4.35; 95% CI=2.62- 7.21). As the number of MetS components accumulated from 3 to 5, RCC risk increased likewise from 4 to 6 times.
CONCLUSIONS: MetS is more prevalent in RCC patients in Turkey compared to controls. Risk increases with the number of coexisting MetS components.

Entities:  

Mesh:

Year:  2014        PMID: 25292088     DOI: 10.7314/apjcp.2014.15.18.7925

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  [Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma].

Authors:  M N Zuo; Y Q DU; L P Yu; X Dai; T Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

2.  Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer.

Authors:  Neil J Kocher; Chris Rjepaj; Haley Robyak; Erik Lehman; Jay D Raman
Journal:  World J Urol       Date:  2016-05-17       Impact factor: 4.226

3.  Metabolic syndrome is associated with improved cancer-specific survival in patients with localized clear cell renal cell carcinoma.

Authors:  Zhenhua Liu; Haifeng Wang; Lian Zhang; Shaobo Li; Yu Fan; Yisen Meng; Shuai Hu; Qian Zhang; Zhisong He; Liqun Zhou; Wenke Han; Wei Yu; Jie Jin
Journal:  Transl Androl Urol       Date:  2019-10

4.  Can we Avoid the Unnecessary Loss of nephrons in the Management of Small Solid Renal Masses? Additional Clinical Parameters to Predict Benign-malign Distinction.

Authors:  Ismail Selvi; Halil Basar
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-03-17

5.  Does obesity impact bladder cancer prognosis?-a long-lasting debate.

Authors:  Fabrizio Dal Moro; Michele Colicchia
Journal:  Transl Androl Urol       Date:  2018-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.